Investors-Gan & Lee

Careers | Investors | Patients and HCPS | Contact us

Careers Investors Patients and HCPS Contact us

Search

# Popular search #

Diabetes Oncology Medical Devices

Investors

Investors Financial Reports IR Appointment

FY2021 Financial Performance Overview

Operating Income (CNY)

3.61billion
Increase by 7.4% YOY
Net Profit Attributable Parent (CNY)

1.45million
Increase by 18.0% YOY
Sales Income in China (CNY)

3.36 Billion
Increase by 2.7% YOY
International Sales Income (CNY)

0.23 Billion
254.4% YOY Increase
R&D Input Ratio (R&D Input/Operating Income)

15.2%
R&D Investment 0.55 Billion CNY
Equity Incentive(Around 600 Employees Granted)

12.0862 Million Shares of Stock Options
2.15% Total Share Capital of the Company
Shareholder Returns in 2021（CNY）

220Million Cash Dividend
15.2% ROE
Profit Distribution Proposal of the Company 2021（CNY）

170Million Cash Dividend

Copyright © 2021 Gan & Lee Pharmaceuticals. All Rights Reserved.

Our websites

Gangan Technology

Subscribe

You are now leaving the Gan & Lee website.

The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.

Continue Back